| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥13.4B | ¥21.1B | -36.3% |
| Operating Income | ¥-4.9B | ¥-4.6B | -8.3% |
| Ordinary Income | ¥-4.1B | ¥-4.0B | -3.2% |
| Net Income | ¥-4.2B | ¥-1.1B | -281.9% |
| ROE | -28.4% | -6.1% | - |
FY2025 Q3 cumulative results show revenue of 1,342 million yen (YoY -36.3%), operating loss of 494 million yen (YoY -8.3% deterioration), ordinary loss of 413 million yen (YoY -3.2% deterioration), and net loss of 410 million yen (YoY -281.9% deterioration). The company continued significant losses across all profit levels despite maintaining a high gross margin of 64.8%. Total assets decreased slightly to 4,972 million yen from 5,010 million yen, while equity declined to 1,465 million yen from 1,780 million yen due to accumulated losses. The equity ratio stands at 29.5%, down from prior levels, reflecting increased financial leverage. Operating margin deteriorated to -36.8% and ROE reached -28.4%, indicating substantial profitability challenges. Cash and deposits of 666 million yen provide coverage of 2.19 times short-term debt, maintaining near-term liquidity despite structural losses.
Revenue declined 763 million yen YoY to 1,342 million yen, driven primarily by reduced sales across major segments. The Renewable Energy segment sales fell 41.2% to 455 million yen from 774 million yen in the prior year, while Beauty & Healthcare sales declined 59.8% to 385 million yen from 958 million yen. Digital Marketing maintained relative stability with 230 million yen compared to 223 million yen previously. A newly established Trading segment contributed 23 million yen following the September 2025 licensing acquisition by consolidated subsidiary UNIVA Hong Kong Trading Limited for pharmaceutical wholesale operations targeting Chinese e-commerce platforms. The Growth Support segment contracted significantly to 108 million yen from prior operations. Cost of sales decreased to 467 million yen, yielding gross profit of 868 million yen at a 64.8% margin, demonstrating strong product-level profitability. However, SG&A expenses of 1,362 million yen (101.6% of revenue) overwhelmed gross profit, resulting in operating loss expansion. The gap between operating loss of 494 million yen and ordinary loss of 413 million yen reflects 81 million yen in net non-operating income, primarily comprising foreign exchange gains of 152 million yen and equity method investment losses of 21 million yen. Special losses of 8 million yen contributed to widening the net loss to 410 million yen. The deterioration from prior net loss of 110 million yen to current 410 million yen represents a 281.9% expansion, attributed to both operational underperformance and diminished one-time gains that partially offset prior-year losses. This reflects a revenue down/profit down pattern, with structural profitability challenges requiring SG&A rationalization and segment revenue recovery.
The Beauty & Healthcare segment recorded revenue of 385 million yen with operating loss of 107 million yen, representing the largest revenue contributor among disclosed segments but carrying substantial losses. Digital Marketing generated revenue of 230 million yen with operating loss of 14 million yen, achieving the smallest loss margin among major segments at -6.3%. The newly established Trading segment contributed 23 million yen in revenue with a minor operating loss of 1 million yen, indicating early-stage operations following pharmaceutical wholesale license acquisition in September 2025. Segment data shows consolidated adjustments of -142 million yen in unallocated corporate expenses, which include management fees revenue of 63 million yen and corporate overhead of 206 million yen. Comparing YoY, Beauty & Healthcare losses improved from 214 million yen to 107 million yen despite sharply lower revenue, suggesting cost structure adjustments. Digital Marketing swung from 3 million yen profit to 14 million yen loss, reflecting margin compression. The Other segment posted revenue of 141 million yen with operating loss of 45 million yen, encompassing media, shared services, and sports businesses. Core business positioning remains fragmented with no segment achieving profitability, though Beauty & Healthcare maintains the largest revenue scale at 28.7% of total consolidated revenue.
[Profitability] ROE of -28.4% deteriorated significantly from prior periods, reflecting accumulated losses eroding shareholder equity. Operating margin of -36.8% indicates substantial operational losses, contrasting with the 64.8% gross profit margin that demonstrates strong product economics offset by excessive overhead. Net profit margin reached -30.6%, driven by SG&A expenses consuming 101.6% of revenue. [Cash Quality] Cash and deposits totaled 666 million yen, providing coverage of 2.19 times against short-term debt of 303 million yen, indicating adequate near-term liquidity. Working capital shows inventories of 295 million yen representing 228 days of inventory on hand based on current sales run rate, signaling potential overstock risk. Accounts receivable of 309 million yen corresponds to approximately 84 days sales outstanding. [Investment Efficiency] Total asset turnover of 0.27 times reflects low revenue generation relative to the 4,972 million yen asset base. Inventory turnover deteriorated with rising inventory levels relative to declining cost of sales. [Financial Health] Equity ratio of 29.5% declined from healthier prior levels as accumulated losses consumed equity, while total liabilities of 3,507 million yen include interest-bearing debt of 1,527 million yen. Current ratio of 159.7% and quick ratio of 144.7% maintain acceptable short-term solvency metrics. Debt-to-equity ratio of 2.39 times and debt-to-capital ratio of 51.0% reflect elevated financial leverage. Long-term loans increased substantially to 1,224 million yen from 422 million yen previously, indicating major debt financing undertaken during the period.
Cash and deposits increased marginally to 666 million yen from prior levels despite substantial operating losses, suggesting external financing inflows offset operating cash consumption. The sharp increase in long-term loans by 700 million yen to 1,224 million yen and short-term borrowings rising by 300 million yen to 303 million yen indicates significant debt financing activity during the period, providing liquidity to sustain operations amid negative profitability. Working capital movements show inventory accumulation of 295 million yen, up 187.8% YoY, tying up cash resources and suggesting slower turnover or strategic stockpiling related to the new Trading segment pharmaceutical operations. Accounts receivable decreased 144 million yen to 309 million yen, releasing some working capital though collection cycles remain extended at approximately 84 days. Accounts payable decreased 39 million yen to 108 million yen, potentially indicating reduced purchasing activity aligned with lower revenue or tighter supplier credit terms. The combination of operating losses, inventory buildup, and debt accumulation suggests cash flow from operations remains negative, with financing activities providing necessary liquidity. Interest-bearing debt totaling 1,527 million yen against cash of 666 million yen yields net debt of 861 million yen, creating interest coverage challenges given the -494 million yen operating loss. The current ratio of 159.7% provides short-term payment capacity, though sustained losses without operational turnaround risk gradual liquidity erosion despite current debt-funded cash reserves.
Ordinary income of -413 million yen versus operating income of -494 million yen reflects net non-operating income contribution of approximately 81 million yen, mitigating operating losses. Non-operating income components include foreign exchange gains of 152 million yen representing a significant positive factor, partially offset by equity method investment losses of 21 million yen and interest expenses of 43 million yen related to increased borrowings. Non-operating income represents 11.3% of revenue, with FX gains constituting the bulk at 11.3% of revenue, indicating meaningful reliance on currency fluctuations rather than operational improvements. The interest coverage ratio of -11.48 times (operating income to interest expense) signals inability to service debt costs from operations, raising sustainability concerns regarding the elevated debt load. Special losses of 8 million yen had minimal impact on the progression from ordinary to net income. The 64.8% gross margin demonstrates strong underlying unit economics, suggesting products/services command favorable pricing, but the 101.6% SG&A ratio overwhelms this advantage. Earnings quality remains weak as losses are driven by structural operational factors rather than one-time events, though FX gains provided temporary relief. The absence of operating cash flow data prevents direct earnings-to-cash conversion analysis, but the inventory buildup and continued losses imply limited cash generation from core operations. Sustained profitability requires SG&A rationalization rather than reliance on favorable non-operating items.
Revenue decline and market competitiveness risk: Revenue decreased 36.3% YoY to 1,342 million yen, with major segments including Renewable Energy down 41.2% and Beauty & Healthcare down 59.8%, indicating potential market share loss, competitive pressure, or structural demand challenges. Persistent top-line contraction without stabilization threatens viability of the business model and compounds fixed cost leverage issues.
Operating leverage and cost structure risk: SG&A expenses of 1,362 million yen consumed 101.6% of revenue, creating operating losses of 494 million yen despite 64.8% gross margins. The high fixed cost base relative to declining revenue demonstrates negative operating leverage, and without meaningful cost reduction or revenue recovery, losses will persist. Corporate overhead adjustments totaling 142 million yen further burden segment profitability.
Financial leverage and debt serviceability risk: Interest-bearing debt increased to 1,527 million yen with long-term loans rising 190.2% to 1,224 million yen and short-term borrowings surging to 303 million yen. Debt-to-equity ratio of 2.39 times and interest coverage of -11.48 times indicate severely constrained ability to service debt from operations. Interest expense of 43 million yen cannot be covered by operating results, creating refinancing risk and potential covenant compliance challenges if losses continue.
[Industry Position] (Reference - Proprietary Analysis)
The company's operating margin of -36.8% significantly underperforms the utilities industry median of 8.6% for 2025-Q3 (IQR: 6.1%-36.5%, n=3), placing it at the bottom of the industry distribution. Net profit margin of -30.6% contrasts sharply with the industry median of 6.6% (IQR: 5.2%-23.7%, n=3), indicating structural profitability challenges well outside normal industry performance ranges. The company's revenue contraction of -36.3% YoY diverges from typical utilities sector stability, suggesting either business model transition issues or significant market disruptions impacting this specific entity. ROE of -28.4% versus positive industry norms reflects deep operational distress and capital erosion inconsistent with sector characteristics. The equity ratio of 29.5% and debt-to-equity of 2.39 times indicate higher financial leverage than typical utilities operators, which often maintain more conservative capital structures given regulated business models. The company's segment diversification across renewable energy, beauty & healthcare, trading, and digital marketing suggests a conglomerate structure rather than pure utilities exposure, potentially explaining performance divergence from industry benchmarks. While classified in the utilities comparison group, the actual business portfolio appears more aligned with diverse growth ventures than traditional utility operations, limiting direct benchmark comparability.
Industry: Utilities (N=3 companies for Q3 2025 benchmarks), Comparison: Prior fiscal periods, Source: Proprietary analysis
Structural profitability recovery remains elusive with operating losses persisting despite high gross margins, indicating the core challenge resides in cost structure rationalization rather than product-level economics. The 64.8% gross margin demonstrates viable unit economics, but SG&A consuming 101.6% of revenue requires aggressive overhead reduction or substantial revenue growth to achieve breakeven. Current trajectory suggests prioritization of cost management over growth investment.
Financial leverage has increased materially with debt-to-equity reaching 2.39 times and interest-bearing debt rising to 1,527 million yen, creating sustainability risks given inability to service debt from operations (interest coverage of -11.48 times). The 190.2% increase in long-term loans to 1,224 million yen suggests recent capital raising to fund operations or expansion, but without operational turnaround, continued debt reliance may approach refinancing constraints. Equity ratio decline to 29.5% from prior levels indicates progressive capital erosion from accumulated losses.
Segment portfolio repositioning underway with new Trading segment launch and significant revenue shifts across existing segments, but none achieved profitability in Q3. Beauty & Healthcare remains largest revenue contributor at 385 million yen but posted 107 million yen operating loss, while Digital Marketing generated 230 million yen with 14 million yen loss. The newly licensed pharmaceutical wholesale Trading operation contributed modestly with 23 million yen revenue and minimal loss, representing potential future growth driver pending scale achievement. Management appears to be pursuing portfolio diversification strategy, though execution risks remain elevated given current loss levels across all segments.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.